AbbVie is a drugmaker known for immunology blockbusters Humira, Skyrizi and Rinvoq, plus Botox.
AbbVie Inc. (ABBV) is expected to report earnings on Friday, October 30, 2026, before the open. Estimated release time 12:00 ET. Consensus EPS estimate is $3.80.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-31 | Jun 2026 qtr | $3.61 | $3.65 | +1.1% | $16.99B |
| 2026-04-29 | Mar 2026 qtr | $2.59 | $2.65 | +2.3% | $15.00B |
| 2026-02-04 | Dec 2025 qtr | $2.65 | $2.71 | +2.3% | $16.62B |
| 2025-10-31 | Sep 2025 qtr | $1.77 | $1.86 | +5.1% | $15.78B |
| 2025-07-31 | Jun 2025 qtr | $2.88 | $2.97 | +3.1% | $15.42B |
| 2025-04-25 | Mar 2025 qtr | $2.38 | $2.46 | +3.4% | $13.34B |
| 2025-01-31 | Dec 2024 qtr | $2.98 | $2.16 | — | $15.10B |
| 2024-10-30 | Sep 2024 qtr | $2.92 | $3.00 | +2.7% | $14.46B |
ABBV has beaten consensus EPS in 7 of its last 7 scored quarters.
ABBV pays a quarterly dividend, currently yielding 2.52%.
| Ex-dividend date | Amount | Paid |
|---|---|---|
| 2026-10-15 | $1.73 | 2026-11-16 |
| 2026-07-15 | $1.73 | 2026-08-14 |
| 2026-04-15 | $1.73 | 2026-05-15 |
| 2026-01-16 | $1.73 | 2026-02-17 |
| 2025-10-15 | $1.64 | 2025-11-14 |
| 2025-07-15 | $1.64 | 2025-08-15 |